Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Lactobacillus casei DG (Enterolactis) bladder colonization and UTI prevention in spinal cord injury patients with intermittent catheterization
2007-007179-18Phase 3Completed
- Sponsor
- SOFAR
- Start
- Apr 2008
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lactobacillus casei DG in urinary tract infection (UTI), sponsored by SOFAR. Primary endpoint: Bladder persistence of Lactobacillus casei DG. Started Apr 2008; status: completed.
02
Drugs
lactobacillus casei DG
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2007-007179-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007179-18.